Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes.
anemia
biosimilar pharmaceuticals
erythropoietin
myelodysplastic syndromes
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
17 Mar 2022
17 Mar 2022
Historique:
received:
20
01
2022
revised:
08
03
2022
accepted:
15
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
26
3
2022
Statut:
epublish
Résumé
This prospective observational study aimed to verify the efficacy of erythropoietin zeta in the treatment of patients with low-risk myelodysplastic syndrome. Patients with low/int-1 IPSS risk and serum erythropoietin level below 500 U/L were enrolled. Treatment consisted of erythropoietin zeta 40,000 U subcutaneously once a week. The primary endpoint was the erythroid response. According to Simon's two-stage statistical design, 36 patients were recruited. The median age was 75 years (range 56-83 years), male/female ratio was 1.1/1, median baseline serum erythropoietin was 57.9 U/L (range 9.4-475 U/L). 53% of patients had low-risk disease, while the remaining had Int-1 risk. After 8 weeks, a significant response (rise in Hb levels of at least 1.5 g/dL) was achieved in 18 patients (50%) out of 36. However, 17 patients did not improve; 8/17 patients pursued the 40,000 U weekly schedule of erythropoietin zeta, and 4/8 (50%) of them reached the erythroid response after 16 weeks. Nine patients underwent dosage doubling (40,000 U twice per week), and 5/9 (55%) of them achieved the erythroid response. Compared with data from the literature, this prospective study revealed that EPO-zeta is a safe and effective therapeutic option in low-risk MDS patients.
Sections du résumé
BACKGROUND
BACKGROUND
This prospective observational study aimed to verify the efficacy of erythropoietin zeta in the treatment of patients with low-risk myelodysplastic syndrome.
METHODS
METHODS
Patients with low/int-1 IPSS risk and serum erythropoietin level below 500 U/L were enrolled. Treatment consisted of erythropoietin zeta 40,000 U subcutaneously once a week. The primary endpoint was the erythroid response. According to Simon's two-stage statistical design, 36 patients were recruited. The median age was 75 years (range 56-83 years), male/female ratio was 1.1/1, median baseline serum erythropoietin was 57.9 U/L (range 9.4-475 U/L). 53% of patients had low-risk disease, while the remaining had Int-1 risk.
RESULTS
RESULTS
After 8 weeks, a significant response (rise in Hb levels of at least 1.5 g/dL) was achieved in 18 patients (50%) out of 36. However, 17 patients did not improve; 8/17 patients pursued the 40,000 U weekly schedule of erythropoietin zeta, and 4/8 (50%) of them reached the erythroid response after 16 weeks. Nine patients underwent dosage doubling (40,000 U twice per week), and 5/9 (55%) of them achieved the erythroid response.
CONCLUSION
CONCLUSIONS
Compared with data from the literature, this prospective study revealed that EPO-zeta is a safe and effective therapeutic option in low-risk MDS patients.
Identifiants
pubmed: 35329991
pii: jcm11061665
doi: 10.3390/jcm11061665
pmc: PMC8951463
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Clin Oncol. 2008 Jul 20;26(21):3607-13
pubmed: 18559873
Oncologist. 2007 Oct;12(10):1264-73
pubmed: 17962620
Eur J Haematol. 1996 Jan-Feb;56(1-2):7-11
pubmed: 8599997
Crit Rev Oncol Hematol. 2015 Dec;96(3):542-54
pubmed: 26324461
Cleve Clin J Med. 2010 Jan;77(1):37-44
pubmed: 20048028
Blood Transfus. 2009 Jan;7(1):49-64
pubmed: 19290081
Pharm Res. 2011 Feb;28(2):386-93
pubmed: 20886265
Cancer. 2009 Feb 15;115(4):706-15
pubmed: 19152429
Ann Oncol. 2008 Mar;19(3):411-9
pubmed: 17872902
Kidney Int Suppl. 2003 Nov;(87):S32-9
pubmed: 14531771
Br J Haematol. 2002 Jul;118(1):174-80
pubmed: 12100145
Blood. 1997 Mar 15;89(6):2079-88
pubmed: 9058730
Br J Haematol. 2003 Jul;122(2):269-71
pubmed: 12846896
N Engl J Med. 1990 Jun 14;322(24):1693-9
pubmed: 2342535
Haematologica. 2002 Dec;87(12):1286-306
pubmed: 12495903
Ann Hematol. 2016 Jun;95(7):1059-65
pubmed: 27091349
Ann Hematol. 2008 Jul;87(7):527-36
pubmed: 18351340
Blood. 2008 Jan 15;111(2):574-82
pubmed: 17940203
Leukemia. 2017 Sep;31(9):1944-1950
pubmed: 28626220
Am J Blood Res. 2011;1(2):160-6
pubmed: 22432077
Med Oncol. 2000 Nov;17 Suppl 1:S17-22
pubmed: 11188781
Ann Hematol. 2020 Jan;99(1):7-19
pubmed: 31650290
NDT Plus. 2009 Jan;2(Suppl_1):i27-i36
pubmed: 19461855
Ann Oncol. 2004 Nov;15(11):1684-90
pubmed: 15520072
Leukemia. 2018 Dec;32(12):2648-2658
pubmed: 29895954
Blood. 2009 Dec 17;114(26):5251-5
pubmed: 19710499
Onkologie. 2009 Apr;32(4):168-74
pubmed: 19372711
Drug Discov Today. 2009 May;14(9-10):495-9
pubmed: 19429509
Oncologist. 2011;16 Suppl 3:35-42
pubmed: 21930833
Blood. 2006 Jul 15;108(2):419-25
pubmed: 16609072
Am J Blood Res. 2012;2(2):136-47
pubmed: 22762033
Ann Hematol. 2014 Aug;93(8):1413-20
pubmed: 24647684
Br J Haematol. 2003 Jan;120(2):187-200
pubmed: 12542475
Cancer Med. 2019 Dec;8(18):7567-7576
pubmed: 31657156
Br J Haematol. 2007 Apr;137(2):125-32
pubmed: 17391492
Leuk Res. 2005 Oct;29(10):1217-9
pubmed: 16111537
J Clin Oncol. 2005 Oct 20;23(30):7594-603
pubmed: 16186598
Haematologica. 2011 Jul;96(7):937-42
pubmed: 21719882
Blood. 2009 Sep 17;114(12):2393-400
pubmed: 19564636